Download the full report (112 p.) - KCE

More documents

Recommendations

Info

76 Interventions in Alzheimer’s Disease KCE Reports 111 6.3.7.3 Cox proportional hazard model We analyzed the impact of patient and treatment characteristics on overall mortality using a Cox Proportional Hazard model. The results of the model are given below. Table 21: Impact of patient and treatment characteristics on overall mortality using a Cox Proportional Hazard model Variable Patients baseline demographics DF HR 95% CI Chi Square p-value Sex (male vs female) 1 2.30 1.96 2.70 103.00
KCE Reports 111 Interventions in Alzheimer’s Disease 77 6.3.8 Patients on Ebixa 6.3.8.1 Patients and setting of first prescription As confirmed also by the Pharmanet data listed above, the number of patients receiving Ebixa prescriptions is small compared with the number of patients on ChEIs. The 299 patients receiving Ebixa prescriptions in the PS/EP in the period 2004-2006 are on average 79.9 years old or about 1 year older than those receiving ChEIs (therapeutic indication is moderately severe and severe AD, MMSE < 15 and > 2). 94 patients (about a third of the patients) had a first Ebixa prescription after institutionalization. A total of 211 patients received Ebixa in 2006. This corresponds to an estimated 211x20= 4022 patients on Ebixa in Belgium in 2006. Based on an increase of 9% from 2006 to 2007 in Pharmanet, one can expect about 5000 patients receiving Ebixa in 2008 in Belgium. In the table below it is shown that 145 out of the 289 patients starting Ebixa during the study period received a ChEI before. Table 2223: Details of prior ChEI use in 145 patients who started Ebixa. Start ARICEPT EXELON REMINYL EBIXA N 1414 461 626 145 End ARICEPT N 1264 30 29 0 PctN 47.77 1.13 1.10 0 EXELON N 22 394 5 0 PctN 0.83 14.89 0.19 0 REMINYL N 37 16 560 0 PctN 1.40 0.60 21.16 0 EBIXA N 91 21 32 145 PctN 3.44 0.79 1.21 5.48
Page 1 and 2:
Pharmaceutical and nonpharmaceutica
Page 3 and 4:
Pharmaceutical and nonpharmaceutica
Page 5 and 6:
KCE reports 111C Interventions in A
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
KCE Reports 111 Interventions in Al
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38: KCE Reports 111 Interventions in Al
Page 87: KCE Reports 111 Interventions in Al
Page 109 and 110: This page is left intentionally bla
Page 111: KCE reports 33 Effects and costs of
show all

Download the full report (112 p.) - KCE

Create successful ePaper yourself

Delete template?

Save as template?